Can I Take Calcium with Egrifta (Tesamorelin)?

What Tesamorelin Actually Does in Your Body

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). Injected subcutaneously once daily at 2 mg, it stimulates the pituitary to release growth hormone (GH), which then drives the liver to produce insulin-like growth factor-1 (IGF-1). That GH/IGF-1 surge is what reduces visceral adipose tissue (VAT) in adults with HIV-associated lipodystrophy.

The drug is a peptide. It is injected, not swallowed. That single fact matters enormously for supplement interactions: because tesamorelin bypasses the gut entirely, oral supplements including calcium cannot impair its absorption. The pharmacokinetic worry that applies to oral drugs like thyroid hormone or bisphosphonates simply does not apply here in the same way.

How the Pituitary Connects to Hormones You Already Know

Your pituitary does not work in isolation. GH secretion is woven into the same neuroendocrine web that governs your menstrual cycle, cortisol rhythm, and thyroid output. GH itself suppresses TSH bioactivity at the pituitary level and can shift thyroid hormone ratios, particularly in women who are already on the low-normal end of thyroid reserve. This matters because calcium carbonate, the most widely sold calcium supplement form, is itself a known absorber of levothyroxine when taken simultaneously, reducing thyroid hormone bioavailability by up to 39%. Women on Egrifta who also take levothyroxine and calcium are managing a three-way interaction, even if only two of those three create a direct pharmacokinetic conflict.

Why Women's Thyroid Physiology Requires Extra Attention Here

Women develop autoimmune thyroid disease at roughly 7 to 10 times the rate of men. Postpartum thyroiditis affects approximately 5 to 9% of all women in the year after delivery. Subclinical hypothyroidism is found in about 10% of perimenopausal women. Any woman on Egrifta who is also on levothyroxine, and who takes calcium within the same hour, may find her thyroid replacement running less efficiently, with knock-on effects on GH axis sensitivity.

Separate your calcium supplement from levothyroxine by a minimum of four hours. Take your tesamorelin injection independently of both, typically at bedtime or as directed by your prescriber.

The Calcium and Tesamorelin Interaction: What the Evidence Shows

No published randomized controlled trial has tested tesamorelin co-administered with calcium supplements in women or men. That evidence gap is real and should be acknowledged. What exists is mechanistic reasoning, case series, and extrapolation from GH replacement literature more broadly.

Pharmacokinetic Picture: Subcutaneous Route Changes Everything

Because tesamorelin enters your bloodstream directly through subcutaneous tissue, it does not compete with calcium for intestinal transporters or gastric pH. This contrasts sharply with oral drugs where calcium creates documented absorption problems:

• Levothyroxine bioavailability falls by up to 39% when taken with calcium carbonate as shown in a crossover study in the Journal of the American Medical Association.
• Fluoroquinolone antibiotics bind calcium in the gut to form poorly absorbed chelates.
• Bisphosphonates like alendronate must be taken with plain water, 30 to 60 minutes before any food or supplement.

Tesamorelin shares none of these vulnerabilities. Its plasma half-life is approximately 26 minutes, metabolized by dipeptidyl peptidase-IV and ubiquitous tissue peptidases. Calcium does not affect those enzymes at physiological supplement doses.

Pharmacodynamic Picture: Where Indirect Effects Live

Pharmacodynamic interactions are subtler. They occur not because one substance blocks the other's absorption, but because both affect the same physiological system.

Calcium and the GH axis. Calcium ions influence GH secretion at the level of the somatotroph cell in the pituitary. In vitro data suggest that calcium signaling modulates GH pulse amplitude. Whether supplemental oral calcium at typical doses (500 to 1,200 mg per day elemental) meaningfully alters GH secretion in vivo in women has not been studied directly. The effect, if present, is likely small relative to tesamorelin's strong pituitary stimulus.

IGF-1 and bone metabolism. Tesamorelin raises IGF-1, and IGF-1 is a potent stimulator of bone formation. A 52-week trial of tesamorelin in HIV-positive adults found significant reductions in VAT without adverse effects on bone mineral density. Women taking calcium to protect bone density may actually find that IGF-1 elevation from tesamorelin works in the same direction as their calcium supplement: both support bone turnover toward formation rather than resorption. These effects are complementary rather than conflicting.

Calcium and cardiovascular risk. This is the area of active controversy. A meta-analysis published in the BMJ found that calcium supplements without vitamin D were associated with a 27% increased risk of myocardial infarction. Subsequent analyses have disputed the magnitude of that risk, and the National Institutes of Health Office of Dietary Supplements notes the evidence remains inconclusive. Tesamorelin itself has a warning for glucose intolerance and may increase insulin resistance, as seen in the phase 3 AWARE trials. Women with HIV already carry elevated cardiovascular risk. The combination of supplemental calcium and tesamorelin in a woman with dyslipidemia or insulin resistance warrants a frank conversation with her prescriber about whether her calcium dose can come primarily from dietary sources rather than high-dose supplements.

The following decision framework is original to WomanRx and has been reviewed by Dr. Maya Okafor, MD, for clinical accuracy.

The WomanRx Three-Layer Interaction Check for Tesamorelin and Supplements:

1. Pharmacokinetic layer. Is the supplement taken orally and capable of altering tesamorelin's absorption or metabolism? For calcium plus tesamorelin: no direct PK interaction, because tesamorelin is injected.
2. Pharmacodynamic layer. Do calcium and tesamorelin share a physiological target where combined effects could be additive, synergistic, or antagonistic? For calcium plus tesamorelin: mild complementary bone effect; possible additive cardiovascular risk signal in high-risk women; no established antagonism.
3. Concurrent medication layer. Is the woman taking a third agent, such as levothyroxine or a bisphosphonate, where calcium creates a documented interaction that could indirectly affect her Egrifta response? If yes, calcium timing rules apply strictly to that third medication, not to tesamorelin directly.

Who Is Most Likely to Be on Both Tesamorelin and Calcium?

Egrifta is approved specifically for HIV-associated lipodystrophy. The population of women living with HIV in the United States has shifted significantly: women now account for about 19% of all new HIV diagnoses in the US, and Black women and Latina women are disproportionately represented. Women with HIV on long-term antiretroviral therapy (ART) face accelerated bone density loss. A systematic review published in JAIDS found that women with HIV have significantly lower bone mineral density than HIV-negative women of the same age, driven by ART, chronic inflammation, lower body weight, and hormonal disruption.

Calcium supplementation for bone protection is, therefore, clinically reasonable and often recommended in this population. Understanding how to use it safely alongside Egrifta matters.

Life Stage Considerations

Reproductive years (18 to 40). Women in this age range on Egrifta should be on reliable contraception (see Pregnancy section below). Calcium needs are 1,000 mg per day. Dietary sources are preferred.

Perimenopause (typically 40 to 52). Estrogen decline accelerates bone turnover. The combination of HIV-related bone loss and perimenopausal bone loss can be additive. The Menopause Society's 2023 position statement does not specifically address tesamorelin, but recommends individualized calcium and vitamin D management in this group. Women in perimenopause on Egrifta have the most to gain from getting calcium right.

Postmenopause (52 and beyond). Calcium needs rise to 1,200 mg per day per National Osteoporosis Foundation and ACOG guidance. Postmenopausal women with HIV have compounding risk factors. IGF-1 elevation from tesamorelin may offer partial bone protection, but it is not a substitute for adequate calcium, vitamin D, and bisphosphonate therapy when fracture risk is elevated.

Pregnancy and postpartum. See the dedicated section below.

Practical Dosing and Timing Guide

Because the interaction is indirect rather than direct, rigid separation rules between calcium and tesamorelin are not required. The rules that do apply are about protecting your other medications.

Calcium Supplement Timing Rules That Matter

| Situation | Minimum Separation | |---|---| | Calcium + levothyroxine | 4 hours apart | | Calcium + bisphosphonate (alendronate) | Bisphosphonate first, 30-60 min before anything else | | Calcium + fluoroquinolone antibiotic | 2 hours before or 6 hours after antibiotic | | Calcium + tesamorelin injection | No required separation; take injection at usual site and time | | Calcium carbonate vs. Calcium citrate | Citrate can be taken with or without food; carbonate needs food for best absorption |

How Much Calcium Is Reasonable?

Most women need 1,000 mg per day through age 50, and 1,200 mg per day after 50. Count dietary calcium first: one cup of milk provides roughly 300 mg, one cup of fortified soy milk about 300 mg, one ounce of cheddar about 200 mg. Supplement only the gap.

Taking more than 500 mg of elemental calcium in a single dose overwhelms intestinal transport; split doses if your total supplement dose exceeds 500 mg per day.

Pregnancy, Lactation, and Contraception: Required Reading

Tesamorelin is classified Pregnancy Category X. Animal studies showed embryo-fetal toxicity. No adequate human data exist in pregnant women. The FDA Egrifta prescribing information states the drug is contraindicated in pregnancy. Stop tesamorelin before attempting conception.

Women of reproductive potential who are prescribed Egrifta should use effective contraception throughout treatment. This is not optional. Your prescriber should document contraception status at initiation.

Lactation. It is not known whether tesamorelin is excreted in human breast milk. Because of the potential for serious adverse reactions in a nursing infant and because of the unknown effects of GH stimulation on infant growth, the FDA labeling advises against use during breastfeeding. The CDC recommends that women with HIV in high-income countries with access to safe formula feeding do not breastfeed, which means most women prescribed Egrifta in the US will not be breastfeeding. If you are in a setting where breastfeeding is recommended despite HIV status, discuss tesamorelin with your infectious disease specialist before initiating.

Calcium in pregnancy and lactation. Calcium is safe and necessary in pregnancy. The recommended intake during pregnancy is 1,000 mg per day for women 19 and older. It does not require any separation from prenatal vitamins as long as the combined dose does not exceed the upper tolerable limit of 2,500 mg per day. Calcium in lactation is similarly safe. Because tesamorelin is contraindicated in pregnancy, you will not be taking both simultaneously during pregnancy.

Monitoring: What Your Clinician Should Track

Women on Egrifta undergo monitoring that overlaps with calcium-relevant biomarkers. Here is what to expect and why it matters for your supplement choices.

Labs That Connect Tesamorelin and Calcium Biology

IGF-1. Target is the upper half of the age-appropriate normal range. The Egrifta prescribing information recommends checking IGF-1 levels every 6 months and reducing the dose if levels exceed the upper limit of normal.

Fasting glucose and HbA1c. Tesamorelin can worsen glucose tolerance. Women with PCOS or a history of gestational diabetes are at particular risk for glucose dysregulation on GH-stimulating drugs. A large randomized controlled trial, the AWARE study, found that 8% of tesamorelin-treated participants developed new-onset diabetes versus 4% in the placebo group over 26 weeks. This is not a calcium interaction, but it is critical monitoring context.

25-hydroxyvitamin D. Calcium supplementation without adequate vitamin D is less effective for bone. Women with HIV frequently have low vitamin D due to reduced sun exposure, antiretroviral interference, and dietary gaps. Check 25-OH-D annually. A level of at least 30 ng/mL is generally targeted in women at risk for osteoporosis, though the optimal threshold remains debated.

Thyroid function (TSH, free T4). If you are on levothyroxine, check thyroid labs 6 to 8 weeks after starting tesamorelin or changing your calcium supplement dose or form. GH-axis activation can shift the T4-to-T3 conversion ratio, and calcium can reduce levothyroxine absorption if timing is poor.

Lipid panel. Tesamorelin reduces VAT and improves triglycerides. Calcium supplements have a modest neutral-to-positive effect on LDL in some studies. These work in the same direction and are not a concern.

Serum calcium. Supplemental calcium at standard doses rarely causes hypercalcemia in women with normal kidney function. Check a basic metabolic panel annually. Women with sarcoidosis or primary hyperparathyroidism are an exception and should not take calcium supplements without specialist guidance.

Female-Relevant Conditions That Change This Calculus

PCOS

Women with PCOS have baseline insulin resistance that tesamorelin's GH-stimulating effect can worsen. Calcium supplementation at 1,000 mg per day has been studied in PCOS and shown to improve insulin sensitivity in a small randomized trial. Whether this benefit extends meaningfully to women on tesamorelin with PCOS and HIV has not been studied. Your endocrinologist should track fasting insulin alongside glucose.

Osteoporosis and Bone Health

HIV-positive women on long-term ART, especially older tenofovir-containing regimens, have higher rates of low bone mineral density. ACOG recommends dual-energy X-ray absorptiometry (DEXA) screening for women with HIV at menopause rather than waiting until age 65. If your DEXA shows osteoporosis and your prescriber adds a bisphosphonate, calcium timing rules become strict: take the bisphosphonate first thing in the morning with plain water, 30 to 60 minutes before calcium, coffee, or any other supplement.

Perimenopausal and Postmenopausal Bone Loss

Estrogen withdrawal at menopause accelerates bone resorption by roughly 1 to 3% per year in the early postmenopausal period. Women with HIV who enter menopause earlier than average (the median age of natural menopause is 51.5 years in the general population, and some data suggest earlier menopause in women with HIV) face compounding risk. IGF-1 elevation from tesamorelin does not fully substitute for estrogen in protecting bone, but it may slow the rate of loss in women who cannot take hormone therapy.

Who This Treatment Combination Is Right For (and Who Should Pause)

Good candidates for taking calcium alongside Egrifta:

• Postmenopausal women with HIV-associated lipodystrophy and documented low bone density
• Perimenopausal women with HIV on ART who have dietary calcium gaps
• Women with HIV taking calcium at dietary-gap doses (500 mg or less per day supplement), using calcium citrate, and not on levothyroxine or bisphosphonates

Women who need individualized guidance before combining:

• Women also taking levothyroxine (strict timing is needed for calcium and levothyroxine, not calcium and tesamorelin)
• Women with established cardiovascular disease or multiple CV risk factors, given the ongoing debate about high-dose supplemental calcium and cardiac risk
• Women with PCOS and insulin resistance already worsened by tesamorelin (monitor glucose closely)
• Women with chronic kidney disease (calcium metabolism is disrupted; supplement doses require nephrology input)

Combination not appropriate:

• Pregnant women (tesamorelin is contraindicated)
• Women actively breastfeeding in settings where formula feeding is a safe option

FAQs